Notice of Interim Results and Capital Markets Day

RNS Number : 0998Y

Tissue Regenix Group PLC

04 September 2015

York, 4 September 2015 -Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 July 2015, on Monday 12^th October.

Additionally, the Group will be hosting a Capital Markets Event on the same date for analysts and investors, with commercial updates from executive and senior management as well as clinical professionals.

For further information regarding the event please contact Tulchan Communications on:

tissueregenix@tulchangroup.com

-Ends-

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

For Further Information

Tissue Regenix Group Plc: +44 1904 567 609

Caitlin Pearson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications: +44 207 353 4200

James Macey White

Victoria Huxster

Matt Low

This information is provided by RNS

The company news service from the London Stock Exchange